Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2014

01-12-2014 | Research Article

A study comparing the effectiveness of three warning labels on the package of driving-impairing medicines

Authors: Bas Emich, Liset van Dijk, Susana P. Monteiro, Johan J. de Gier

Published in: International Journal of Clinical Pharmacy | Issue 6/2014

Login to get access

Abstract

Background Several medicines are known to potentially impair patients’ driving fitness. Appropriate communication towards patients about this risk can be supported by the use of package warning labels. Objective To compare the effectiveness of a standing practice yellow/black label—with written warning—with a newly developed rating model in communicating risk on driving-impairing medicines (DIMs). Furthermore, the added value of a side-text in the rating model was determined. Setting Community pharmacies in the Netherlands. Method In a cross-sectional study, patients with a first dispensing of a DIM were asked by their community pharmacists (n = 38) to fill out a written questionnaire to compare each of the three warning labels. A 2 [yellow/black label vs. rating model (pair 1) and rating model with side-text vs. rating model without side-text (pair 2)] × 3 [category of driving-impairment: I = minor risk, II = moderate risk, III = severe risk] design was used. The category of driving-impairment varied per respondent, depending on the DIM the patient collected. Main outcome measure: (1) estimated level of driving risk valued by patients (2) intention to change driving behaviour after seeing the warning label. Results An estimated number of 992 patients were approached. As 298 questionnaires were analysed, the net response rate was 30 %. With the yellow/black label, respondents considered DIMs of all three categories of driving-impairment to equally impair driving fitness, while with the rating model the estimated risk was higher when the category referred to a higher level of driving-impairment. Addition of a side-text to the rating model resulted in a significantly higher estimated level of driving risk and a significant increase in intention to change driving behaviour. Only 8.0 % of the patients using a category III DIM estimated the level of driving risk correctly when seeing the yellow/black label, while this was 26.7 % for the rating model and 43.0 % for the rating model with side-text. Conclusion The yellow/black label, which is standing practice in the Netherlands, is less effective in terms of estimated risk and intention to change driving behaviour, compared to a newly developed rating model. This model is even more effective when a side-text is added. Implementation of the rating model in clinical practice should be considered.
Literature
1.
go back to reference Ravera S, Monteiro SP, de Gier JJ, van der Linden T, Gómez-Talegón T, Álvarez FJ, et al. A European approach to categorizing medicines for fitness to drive: outcomes of the DRUID project. Br J Clin Pharmacol. 2012;74(6):920–31.PubMedCentralPubMedCrossRef Ravera S, Monteiro SP, de Gier JJ, van der Linden T, Gómez-Talegón T, Álvarez FJ, et al. A European approach to categorizing medicines for fitness to drive: outcomes of the DRUID project. Br J Clin Pharmacol. 2012;74(6):920–31.PubMedCentralPubMedCrossRef
2.
go back to reference Corsenac P, Lagarde E, Gadegbeku B, Delorme B, Tricotel A, Castot A, et al. Road traffic crashes and prescribed methadone and buprenorphine: a French registry-based case-control study. Drug Alcohol Depend. 2012;123(1–3):91–7.PubMedCrossRef Corsenac P, Lagarde E, Gadegbeku B, Delorme B, Tricotel A, Castot A, et al. Road traffic crashes and prescribed methadone and buprenorphine: a French registry-based case-control study. Drug Alcohol Depend. 2012;123(1–3):91–7.PubMedCrossRef
3.
go back to reference Engeland A, Skurtveit S, Mørland J. Risk of road traffic accidents associated with the prescription of drugs: a registry-based cohort study. Ann Epidemiol. 2007;17(8):597–602.PubMedCrossRef Engeland A, Skurtveit S, Mørland J. Risk of road traffic accidents associated with the prescription of drugs: a registry-based cohort study. Ann Epidemiol. 2007;17(8):597–602.PubMedCrossRef
4.
go back to reference Kelly E, Darke S, Ross J. A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. Drug Alcohol Rev. 2004;23(3):319–44.PubMedCrossRef Kelly E, Darke S, Ross J. A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. Drug Alcohol Rev. 2004;23(3):319–44.PubMedCrossRef
5.
go back to reference Orriols L, Queinec R, Philip P, Gadegbeku B, Delorme B, Moore N, et al. Risk of injurious road traffic crash after prescription of antidepressants. J Clin Psychiatry. 2012;73(8):1088–94.PubMedCrossRef Orriols L, Queinec R, Philip P, Gadegbeku B, Delorme B, Moore N, et al. Risk of injurious road traffic crash after prescription of antidepressants. J Clin Psychiatry. 2012;73(8):1088–94.PubMedCrossRef
6.
go back to reference Verster JC, Volkerts ER. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol. 2004;92(3):294–303.PubMedCrossRef Verster JC, Volkerts ER. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol. 2004;92(3):294–303.PubMedCrossRef
7.
go back to reference Verster JC, Veldhuijzen DS, Patat A, Olivier B, Volkerts ER. Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr Drug Saf. 2006;1(1):63–71.PubMedCrossRef Verster JC, Veldhuijzen DS, Patat A, Olivier B, Volkerts ER. Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr Drug Saf. 2006;1(1):63–71.PubMedCrossRef
10.
go back to reference Davis RE, Dolan G, Thomas S, Atwell C, Mead D, Nehammer S, et al. Exploring doctor and patient views about risk communication and shared decision-making in the consultation. Health Expect. 2003;6(3):198–207.PubMedCrossRef Davis RE, Dolan G, Thomas S, Atwell C, Mead D, Nehammer S, et al. Exploring doctor and patient views about risk communication and shared decision-making in the consultation. Health Expect. 2003;6(3):198–207.PubMedCrossRef
11.
go back to reference Edwards A, Elwyn G. How should effectiveness of risk communication to aid patients’ decisions be judged?: a review of the literature. Med Decis Making. 1999;19(4):428–34.PubMedCrossRef Edwards A, Elwyn G. How should effectiveness of risk communication to aid patients’ decisions be judged?: a review of the literature. Med Decis Making. 1999;19(4):428–34.PubMedCrossRef
12.
go back to reference Edwards A, Elwyn G, Hood K, Robling M, Atwell C, Holmes-Rovner M, et al. The development of COMRADE—a patient-based outcome measure to evaluate the effectiveness of risk communication and treatment decision making in consultations. Patient Educ Couns. 2003;50(3):311–22.PubMedCrossRef Edwards A, Elwyn G, Hood K, Robling M, Atwell C, Holmes-Rovner M, et al. The development of COMRADE—a patient-based outcome measure to evaluate the effectiveness of risk communication and treatment decision making in consultations. Patient Educ Couns. 2003;50(3):311–22.PubMedCrossRef
14.
go back to reference Thomson R, Edwards A, Grey J. Risk communication in the clinical consultation. Clin Med. 2005;5(5):465–9.PubMedCrossRef Thomson R, Edwards A, Grey J. Risk communication in the clinical consultation. Clin Med. 2005;5(5):465–9.PubMedCrossRef
15.
go back to reference Edwards A, Hood K, Matthews E, Russell D, Russell I, Barker J, et al. The effectiveness of one-to-one risk-communication interventions in health care: a systematic review. Med Decis Making. 2000;20(3):290–7.PubMedCrossRef Edwards A, Hood K, Matthews E, Russell D, Russell I, Barker J, et al. The effectiveness of one-to-one risk-communication interventions in health care: a systematic review. Med Decis Making. 2000;20(3):290–7.PubMedCrossRef
16.
go back to reference Wheeler A, Crump K, Lee M, Li L, Patel A, Yang R, Zhao J, Jensen M, et al. Collaborative prescribing: a qualitative exploration of a role for pharmacists in mental health. Res Soc Adm Pharm. 2012;8(38):179–92.CrossRef Wheeler A, Crump K, Lee M, Li L, Patel A, Yang R, Zhao J, Jensen M, et al. Collaborative prescribing: a qualitative exploration of a role for pharmacists in mental health. Res Soc Adm Pharm. 2012;8(38):179–92.CrossRef
17.
go back to reference Hill LH, Roslan MR. Using visual concept mapping to communicate medication information to chronic disease patients with low literacy: a preliminary study. Paper presented at first international conference on concept mapping; September 14–17, 2004; Navarra, Spain. Hill LH, Roslan MR. Using visual concept mapping to communicate medication information to chronic disease patients with low literacy: a preliminary study. Paper presented at first international conference on concept mapping; September 14–17, 2004; Navarra, Spain.
18.
go back to reference Stout QF, de Gier JJ. Effect van de geel-zwarte rijvaardigheidssticker op geneesmiddelen [Effect of the yellow–black warning label for driving on drugs; article in Dutch]. Pharmaceutisch Weekblad. 1982;117:449–52. Stout QF, de Gier JJ. Effect van de geel-zwarte rijvaardigheidssticker op geneesmiddelen [Effect of the yellow–black warning label for driving on drugs; article in Dutch]. Pharmaceutisch Weekblad. 1982;117:449–52.
19.
go back to reference Veldhuijzen DS, van Wijck AJ, Verster JC, Kalkman CJ, Kenemans JL, Olivier B, Volkerts ER. The impact of chronic pain patients’ psychotropic drug knowledge and warning labels on the decision whether to drive a car or not. Traffic Inj Prev. 2006;7(4):360–4.PubMedCrossRef Veldhuijzen DS, van Wijck AJ, Verster JC, Kalkman CJ, Kenemans JL, Olivier B, Volkerts ER. The impact of chronic pain patients’ psychotropic drug knowledge and warning labels on the decision whether to drive a car or not. Traffic Inj Prev. 2006;7(4):360–4.PubMedCrossRef
21.
go back to reference Monteiro SP, Huiskes R, van Dijk L, van Weert JCM, de Gier JJ. How effective are pictograms in communicating risk about driving-impairing medicines? Traffic Inj Prev. 2013;14(3):299–308.PubMedCrossRef Monteiro SP, Huiskes R, van Dijk L, van Weert JCM, de Gier JJ. How effective are pictograms in communicating risk about driving-impairing medicines? Traffic Inj Prev. 2013;14(3):299–308.PubMedCrossRef
23.
go back to reference Fierro I, Gómez-Talegón T, Álvarez FJ. The Spanish pictogram on medicines and driving: the population’s comprehension of and attitudes towards its use on medication packaging. Accid Anal Prev. 2013;50:1056–61.PubMedCrossRef Fierro I, Gómez-Talegón T, Álvarez FJ. The Spanish pictogram on medicines and driving: the population’s comprehension of and attitudes towards its use on medication packaging. Accid Anal Prev. 2013;50:1056–61.PubMedCrossRef
24.
go back to reference Smyth T, Sheehan M, Siskind V, Mercier-Guyon C, Mallaret M. Consumer perceptions of medication warnings about driving: a comparison of French and Australian labels. Traffic Inj Prev. 2013;14(6):557–64.PubMedCrossRef Smyth T, Sheehan M, Siskind V, Mercier-Guyon C, Mallaret M. Consumer perceptions of medication warnings about driving: a comparison of French and Australian labels. Traffic Inj Prev. 2013;14(6):557–64.PubMedCrossRef
25.
go back to reference Legrand SA, Boets S, Meesmann U, Verstraete AG. Medicines and driving: evaluation of training and software support for patient counselling by pharmacists. Int J Clin Pharm. 2012;34(4):633–4.PubMedCrossRef Legrand SA, Boets S, Meesmann U, Verstraete AG. Medicines and driving: evaluation of training and software support for patient counselling by pharmacists. Int J Clin Pharm. 2012;34(4):633–4.PubMedCrossRef
26.
go back to reference Dowse R, Ehlers M. Medicine labels incorporating pictograms: do they influence understanding and adherence? Patient Educ Couns. 2005;58(1):63–70.PubMedCrossRef Dowse R, Ehlers M. Medicine labels incorporating pictograms: do they influence understanding and adherence? Patient Educ Couns. 2005;58(1):63–70.PubMedCrossRef
27.
go back to reference Katz MG, Kripalani S, Weiss BD. Use of pictorial aids in medication instructions: a review of the literature. Am J Health Syst Pharm. 2006;63(23):2391–7.PubMedCrossRef Katz MG, Kripalani S, Weiss BD. Use of pictorial aids in medication instructions: a review of the literature. Am J Health Syst Pharm. 2006;63(23):2391–7.PubMedCrossRef
28.
go back to reference Montagne M. Pharmaceutical pictograms: a model for development and testing for comprehension and utility. Res Soc Adm Pharm. 2013;9(5):609–20.CrossRef Montagne M. Pharmaceutical pictograms: a model for development and testing for comprehension and utility. Res Soc Adm Pharm. 2013;9(5):609–20.CrossRef
29.
go back to reference Stevens J. Applied multivariate statistics for the social sciences. London: Lawrence Erlbaum Associates; 2002. Stevens J. Applied multivariate statistics for the social sciences. London: Lawrence Erlbaum Associates; 2002.
30.
go back to reference SFK (Stichting Farmaceutische Kengetallen). Rijden onder invloed [Driving under influence; article in Dutch]. Pharmaceutisch Weekblad, 2009;144(26):18. SFK (Stichting Farmaceutische Kengetallen). Rijden onder invloed [Driving under influence; article in Dutch]. Pharmaceutisch Weekblad, 2009;144(26):18.
31.
go back to reference Wilby K, Marra CA, da Silva JH, Grubisic M, Harvard S, Lynd LD. Randomized controlled trial evaluating pictogram augmentation of HIV medication information. Ann Pharmacother. 2011;45(11):1378–83.PubMedCrossRef Wilby K, Marra CA, da Silva JH, Grubisic M, Harvard S, Lynd LD. Randomized controlled trial evaluating pictogram augmentation of HIV medication information. Ann Pharmacother. 2011;45(11):1378–83.PubMedCrossRef
Metadata
Title
A study comparing the effectiveness of three warning labels on the package of driving-impairing medicines
Authors
Bas Emich
Liset van Dijk
Susana P. Monteiro
Johan J. de Gier
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 6/2014
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-014-0010-2

Other articles of this Issue 6/2014

International Journal of Clinical Pharmacy 6/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.